Scisparc ltd. and clearmind medicine inc. collaboration yields 3rd patent application for the treating of obesity and metabolic syndromes

Tel aviv, israel, sept. 22, 2022 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (“company” or “scisparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that clearmind medicine inc. (“clearmind”) (cse: cmnd), (otc: cmndf), (fse: cwy0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the company's collaboration with clearmind.
SPRC Ratings Summary
SPRC Quant Ranking